MSH2 and cancer: Cancers usually acquire MMRd through defects in the MutSα mismatch recognition complex (usually MSH2 or MSH6 mutations) or the MutLα mismatch correction complex (mostly MLH1 promoter hypermethylation and transcriptional silencing, or occasionally MLH1 or PMS2 mutations).